SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Hims & Hers Health Inc - Ordinary Shares - Class A

Hims & Hers Health Inc

Hims & Hers Health is seeing a dramatic surge following reports of an impending partnership with Novo Nordisk to sell GLP-1 obesity drugs on its platform, a development that broke after hours and has ignited intense speculation about a massive short squeeze.

United States Oil Fund LP - United States Oil Fund

United States Oil Fund

The United States Oil Fund is trending as the escalating U.S.-Iran conflict and near-total disruption of the Strait of Hormuz drive record weekly gains in crude oil prices, fueling community debate between expectations of further parabolic surges and anticipation of a sharp correction due to potential interventions.

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsværd, Denmark.

Novo Nordisk - ADR

Novo Nordisk A/S

Novo Nordisk is trending amid reports of a partnership with Hims & Hers to distribute its weight-loss drugs and recent FDA crackdowns on unapproved compounded GLP-1s, bolstering branded market share. The community is discussing NVO's perceived undervaluation and the rapid adoption of its oral Wegovy, despite its stock's more muted reaction compared to its new partner's.

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Capricor Therapeutics Inc

Capricor Therapeutics is trending as the community celebrates the imminent departure of a prominent FDA official, seen as a major barrier to the accelerated approval of its Duchenne Muscular Dystrophy therapy, Deramiocel, fueling strong bullish sentiment ahead of a key Phase 3 data presentation at a medical conference.

Aventus Network

Aventus Network (AVT) is capturing attention following the formal incorporation of its DAO in the UAE and strategic partnerships to bolster its Aventus Cloud offerings. The community is buzzing about AVT's enterprise-grade technology, Polkadot integration, and low market capitalization, anticipating a significant breakout.

Freysa is a suite of Personal AI products with a focus on human agency, liquid democracy and decentralized ownership. The mission of the team is dedicated to creating new systems that enable all humans to govern + co-own AI resources, and not just a select few. Current products include: (1) Freysa as the world’s first sovereign agent that holds her own cryptographic keys, enabling her to act autonomously without human control. Freysa evolves publicly through a multi-act interactive story. (2) Enchanted as a personalized Digital Twin for every human. Conversations are persistent and twins retain context over time, remembering human preferences and building an evolving model of you. (3) Esper as a browser tool that feeds authenticated real-world data into each human’s Digital Twin.

Flourishing AI

Flourishing AI (FAI) is trending with an explosive price surge, driven by an enthusiastic community highlighting its AI token narrative and perceived significant 'upgrades,' while others caution about potential pump-and-dump behavior.

Ondas, Inc. engages in the development, marketing, and sale of wireless radio systems for secure, wide area mission-critical business-to-business networks. It operates through the Ondas Networks and Ondas Autonomous Systems segments. The Ondas Networks segment provides wireless connectivity solutions enabling mission-critical Industrial Internet applications and services. The Ondas Autonomous Systems segment designs, develops, and markets commercial drone solutions via the Optimus System and Scout System. The company was founded on December 22, 2014 and is headquartered in West Palm Beach, FL.

Ondas Inc.

Ondas Inc

Ondas (ONDS) is experiencing high volatility as new $6 million counter-drone system orders from Middle East defense clients compete with market disappointment over its exclusion from the initial DoD 'Gauntlet' for offensive drones. Investors are actively debating the significance of its defensive technology specialization and growing backlog against perceived competitive setbacks and past dilution, amidst escalating global demand for drone solutions.

Volatility Shares Trust - 1x Short VIX Futures ETF

Volatility Shares 1x Short VIX Futures ETF

SVIX is trending as traders navigate persistent market volatility, debating if the VIX will sustain elevated levels amid evolving geopolitical and economic policy signals, or if a volatility crush will benefit this inverse ETF. The community is actively discussing SVIX's perceived decay and comparing its performance to leveraged VIX products as a strategy to short market fear.

Red Cat Holdings, Inc. provides products, services and solutions to the drone industry. It also engages in the provision of distributed data storage, analytics and services for the drone industry.The firm product include Dronebox, which is a blockchain technology that records, stores and analyzes flight data and information from a drone. It operates through the Enterprise Segment. The Enterprise Segment will focus on developing a hardware enabled software platform of services and solutions to government and commercial enterprises and the military. The company was founded by Jeffrey M. Thompson in February 1984 and is headquartered in San Juan, Puerto Rico.

Red Cat Holdings Inc

Red Cat Holdings is seeing massive trading volume and high volatility as the community reacts to its Teal drone not making the top 11 in a key defense program. While some express disappointment, many investors remain bullish, emphasizing the broader "Drone Dominance" initiative, upcoming earnings, and potential for significant military contracts for other drone platforms and uncrewed surface vessels.

ProShares Trust - ProShares Ultra VIX Short-Term Futures ETF 1.5x Shares

ProShares Ultra VIX Short-Term Futures ETF

ProShares Ultra VIX Short-Term Futures ETF (UVXY) is trending due to heightened geopolitical tensions, particularly surrounding the US and Iran, which is driving discussions around market volatility. The community is actively debating whether to capitalize on potential spikes, with some expecting significant upside, or to short the ETF, viewing it as a 'widowmaker' designed for long-term decay.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Shares of Predictive Oncology Inc. (POAI) drew significant interest from retail investors after the company on Monday announced the pricing of two private placement transactions to raise an aggregate of approximately $344.4 million, which will support its adoption of a digital asset treasury strategy.The firm stated that the principal holding will be the native utility token of the Aethir ecosystem.The two private transactions are expected to close on or about October 2. The funds will be used to support the company’s digital asset treasury strategy, for the acquisition of ATH in the open market, and for working capital and general corporate purposes, the company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://investors.predictive-oncology.com/news-releases/news-release-details/predictive-oncology-inc-announces-private-placements-344-million">stated</a>.Last week, Predictive Oncology also <a href="https://stocktwits.com/news-articles/markets/equity/predictive-oncology-shares-tumble-on-reverse-stock-split-announcement/chDl1r4R3IR">announced</a> a 1-for-15 reverse stock split of its issued and outstanding shares of common stock, which became effective at 12:01 a.m. on Tuesday, Sept. 30, 2025. The split is designed to bring the company into compliance with Nasdaq’s minimum bid requirement for continued listing on the exchange. Following the split, the company lowered its shares of common stock to 762,000 from over 11.4 million.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/POAI">POAI stock</a> rose from ‘neutral’ to ‘extremely bullish’ territory over the past 24 hours, while message volume stayed at ‘extremely high’ levels.Predictive Oncology is an AI-driven drug development and discovery company. For the second quarter, the company reported diluted loss per common share of $0.22. The company ended the quarter with $506,078 in cash and cash equivalents, compared to $611,822 as of Dec. 31, 2024, and a stockholders' deficit of approximately $1.7 million.Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/why-spotify-stock-is-slipping-2-in-premarket/chDDP1nR3Bg">Why Spotify Stock Is Slipping 2% In Premarket</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Stock market down on a black background. | Image source: Yuichiro Chino via Getty Images

Predictive Oncology Stock Receives Significant Investor Interest Today – Here Are Two Important Developments

The company on Monday announced the pricing of two private placement transactions to raise an aggregate of approximately $344.4 million.

Equity

The company on Monday announced the pricing of two private placement transactions to raise an aggregate of approximately $344.4 million.


Shares of Predictive Oncology Inc. (POAI) tumbled 19% on Thursday after the company announced that it will effect a 1-for-15 reverse stock split of its issued and outstanding shares of common stock.The reverse stock split will <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/news-release/2025/09/25/3156239/37244/en/Predictive-Oncology-Announces-1-for-15-Reverse-Stock-Split.html">become</a> effective at 12:01 a.m. on Tuesday, September 30, the company said. The reverse stock split is primarily aimed at bringing the company into compliance with Nasdaq’s minimum bid requirement for continued listing on the bourse.At the effective time of the reverse stock split, every 15 shares of Predictive Oncology’s issued and outstanding common stock will be combined automatically into one share of common stock. While the company currently has over 11.4 million shares of common stock, it will be reduced to about 762,000 after the split, the firm added.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/POAI">POAI stock</a> stayed within the ‘extremely bullish’ territory over the past 24 hours, while message volume stayed at ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:576/63;" src="https://news.stocktwits-cdn.com/Screenshot_2025_09_25_at_2_16_32_PM_png_9c3fdd1117.webp" alt="POAI's Sentiment Meter and Message Volume as of 2:16 p.m. ET on Sept. 25, 2025 | Source: Stocktwits" width="576" height="63"><figcaption>POAI's Sentiment Meter and Message Volume as of 2:16 p.m. ET on Sept. 25, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user opined that the stock will fall below $0.50 before the reverse stock split becomes effective.<stembedurl>https://stocktwits.com/MillionaireTrader555/message/629988968</stembedurl>Predictive Oncology is an AI-driven drug development and discovery company. For the second quarter, the company reported diluted loss per common share of $0.22. The company ended the quarter with $506,078 in cash and cash equivalents, compared to $611,822 as of December 31, 2024, and a stockholders' deficit of approximately $1.7 million.POAI stock is up 17% this year and approximately 22% over the past 12 months.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/tiziana-life-sciences-stock-rises-on-advancing-second-asset/chDl0MtR34z">Tiziana Life Sciences Shares Rise On Advancing Second Asset Besides Foralumab: Retail Thinks Stock Has ‘So Much Potential’</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Predictive Oncology Shares Tumble 19% On Reverse Stock Split Announcement – More Details Inside

The reverse stock split is primarily intended to bring the company into compliance with Nasdaq’s minimum bid requirement for continued listing on the exchange.

Shares of Predictive Oncology Inc. (POAI) fell to their lowest level in a month on Thursday, drawing&nbsp;significant retail attention. Renovaro announced that its 2025 lawsuit to enforce a merger agreement with POAI will proceed on an expedited trial schedule.Renovaro, a TechBio company specializing in diagnostics and genetically enhanced cancer therapies, said the Delaware Court of Chancery approved its motion to fast-track a&nbsp;lawsuit filed earlier this month.&nbsp;Predictive Oncology shares closed down 10.1% at $0.98 on Thursday, holding steady in after-hours trading.The case stems from an alleged breach of a binding merger agreement signed on Jan. 1.According to Renovaro’s complaint, the agreement required POAI to merge into Renovaro in exchange for a new class of preferred stock.&nbsp;Renovaro claims that Predictive Oncology violated exclusivity and good faith clauses by raising $545,000 in a public offering in February and attempting to terminate the agreement unilaterally in April.The company&nbsp;now seeks specific performance, injunctive relief, and damages for the alleged breaches.In its Form 10-Q filing dated May 14, Predictive Oncology said that while the two companies entered into a binding letter of intent for the merger on Jan. 1, and extended the agreement’s termination date to March 31, no definitive purchase agreement was signed by that date.&nbsp;Predictive Oncology’s board notified Renovaro on April 3 that merger discussions were discontinued and that the company has no further obligations under the letter of intent or extension agreement.&nbsp;The company dismissed Renovaro’s lawsuit as without merit and said it intends to “vigorously” contest the case.The dispute unfolds as Predictive Oncology continues to promote its use of AI and machine learning in drug discovery, citing access to a biobank of over 150,000 live tumor samples.&nbsp;The company said its platform modeled tumor responses for 21 previously untested compounds.On Stocktwits, retail sentiment was ‘bullish’ amid a 2,200% surge in 24-hour message volume.One retail user said they held no position in POAI but were invested in Renovaro and hoped the merger would be completed.&nbsp;<stembedurl>https://stocktwits.com/Stengaard1/message/615590359</stembedurl>Another user suggested POAI could deliver unexpected gains, predicting the stock might rally suddenly.<stembedurl>https://stocktwits.com/EarlofLondon/message/615526666</stembedurl>The stock has risen 6.5% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Predictive Oncology Stock Hits 1-Month Low Amid Renovaro Legal Clash, But Retail Leans Bullish

Renovaro said the Delaware Court of Chancery had approved an expedited trial schedule for the lawsuit it filed to enforce a binding merger agreement with Predictive Oncology.

Axe Compute, Inc. engages in the application of artificial intelligence medicine and the provision of cleared STREAMWAY System for automated, direct-to-drain medical fluid disposal, and associated products. It operates through the following segments: Helomics, zPREDICTA, Skyline, Soluble, and Corporate. The Helomics segment includes contract services that include the application of AI, partnering projects, and clinical testing. The zPREDICTA segment specializes in organ-specific disease models that provide 3D reconstruction of human tissues accurately representing each disease state and mimicking drug response enabling accurate testing of anticancer agents. The Skyline segment consists of the STREAMWAY System product sales, and its TumorGenesis subsidiary is included within the Corporate segment. The Soluble segment provides services using an automated system that conducts self-interaction chromatography screens, using additives and excipients commonly included in protein formulations resulting in soluble and physically stable formulations for biologics. The company was founded by Lawrence W. Gadbaw, Peter L. Morawetz, and Jeffrey K. Drogue on April 23, 2002 and is headquartered in Pittsburgh, PA.

POAI
Predictive Oncology Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest POAI News

POAIPredictive Oncology Inc